Meeting
2018 ASCO Annual Meeting
Clinical outcomes with cumulative tumor suppressor gene (TSG) alterations in castration sensitive (CSPC) and resistant (CRPC) prostate cancer.
Authors
Anis Hamid
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA
Anis Hamid , Kathryn P. Gray , Grace Shaw , Laura E MacConaill , Carolyn Evan , Brandon David Bernard , Massimo Loda , Atish Dipankar Choudhury , Christopher Sweeney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5055)
DOI
10.1200/JCO.2018.36.15_suppl.5055
Abstract #
5055
Poster Bd #
282
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Germline APC (I1307K) mutation and clinical outcomes in prostate cancer.
First Author: Minas P. Economides
Poster
2023 ASCO Genitourinary Cancers Symposium
Germline APC (I1307K) mutation and clinical outcomes in prostate cancer.
First Author: Minas P. Economides
Poster
2018 ASCO Annual Meeting
Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant TMPRSS2:ERG fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).
First Author: Leszek Kotula
Poster
2018 Genitourinary Cancers Symposium
Difference of genomic signatures and opportunities for targeted and immunotherapies in castrate resistant TMPRSS2:ERG fusion positive and TMPRSS2:ERG wild type refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).
First Author: Gennady Bratslavsky